Esketamine Suppliers & Bulk Manufacturers
Available Forms: Nasal spray
Available Strengths: 28 mg
Reference Brands: Spravato (USA/EU)
Category:
Psychiatry / Mental Health
Esketamine is available in Nasal spray
and strengths such as 28 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Esketamine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Esketamine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Esketamine nasal spray is a novel antidepressant specifically indicated for treatment-resistant depression (TRD) in adults. It provides a rapid-acting option for patients with major depressive disorder (MDD) who have not responded adequately to conventional antidepressant therapies. Esketamine is the S-enantiomer of ketamine and acts as an NMDA receptor antagonist, modulating glutamatergic neurotransmission in the brain to improve mood and cognitive function.
Major depressive disorder is a widespread mental health condition affecting millions globally, characterized by persistent low mood, loss of interest or pleasure in daily activities, and associated symptoms such as fatigue, weight changes, psychomotor retardation, feelings of worthlessness, impaired concentration, and suicidal thoughts. Esketamine offers a valuable therapeutic approach for patients with severe or refractory depression, providing benefits in both symptom relief and functional improvement. Administered intranasally under medical supervision, it is generally well-tolerated, though monitoring for potential adverse effects, including dissociation and blood pressure changes, is recommended. Esketamine represents an important advancement in the management of MDD, particularly for patients with limited response to traditional antidepressants.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing